Lv31
340 积分 2023-05-06 加入
Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management
4天前
已完结
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy
12天前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
13天前
已完结
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
16天前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
18天前
已完结
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy
1个月前
已完结
A mixed blessing for liver transplantation patients — Rapamycin
1个月前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
1个月前
已完结
Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17
1个月前
已关闭
Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years
1个月前
已完结
皖公网安备34019202002308
